Effect of GLP‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

AIMS: Schizophrenia is associated with cardiovascular co‐morbidity and a reduced life‐expectancy of up to 20 years. Antipsychotics are dopamine D(2) receptor antagonists and are the standard of medical care in schizophrenia, but the drugs are associated with severe metabolic side effects such as obe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Obes Metab
Päätekijät: Ishøy, Pelle L., Knop, Filip K., Broberg, Brian V., Bak, Nikolaj, Andersen, Ulrik B., Jørgensen, Niklas R., Holst, Jens J., Glenthøj, Birte Y., Ebdrup, Bjørn H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2016
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299524/
https://ncbi.nlm.nih.gov/pubmed/27717222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12795
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia